Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient.

@article{Stempak2005CytochromeP2,
  title={Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient.},
  author={Diana Stempak and Bonny L. Bukaveckas and Mark W. Linder and Gideon Koren and Sylvain Baruchel},
  journal={Clinical pharmacology and therapeutics},
  year={2005},
  volume={78 3},
  pages={
          309-10
        }
}
BETA

Similar Papers

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS

Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite

  • Archives of pharmacal research
  • 2017
VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast

  • Archives of pharmacal research
  • 2016
VIEW 3 EXCERPTS
CITES BACKGROUND

Clinical use and pharmacological properties of selective COX-2 inhibitors

  • European Journal of Clinical Pharmacology
  • 2007
VIEW 1 EXCERPT
CITES BACKGROUND

Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?

  • Drug metabolism and disposition: the biological fate of chemicals
  • 2005
VIEW 1 EXCERPT
CITES BACKGROUND